Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 6/20 | 0.40 |
| ▸ | PPARG | P37231 | 5/20 | 0.40 |
| ▸ | PPARD | Q03181 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EPOR | P19235 | 1/20 | 0.38 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.37 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447295 | 0.83 | POLB (0.43) | TSHRPPARGKDM4EALDH1A1GAA | |
| SCHEMBL5431705 | 0.83 | PPARG (0.48) | TSHRPPARAPPARGCYSLTR2CYSLTR1 | |
| SCHEMBL5440285 | 0.83 | PPARA (0.53) | PPARAPPARGPPARDKDM4EALDH1A1 | |
| SCHEMBL5427774 | 0.78 | PPARA (0.42) | TSHRPPARAPPARGL3MBTL1 | |
| SCHEMBL27558296 | 0.76 | MAOA (0.43) | TSHRCYSLTR2CYSLTR1GRM5KMT2A | |
| SCHEMBL5443771 | 0.76 | PPARG (0.51) | PPARAPPARGPPARDALDH1A1EPOR | |
| SCHEMBL6527084 | 0.76 | MAPT (0.42) | TSHRKDM4EALDH1A1SMN1; SMN2EPOR | |
| SCHEMBL5430363 | 0.75 | PPARG (0.48) | TSHRPPARGALDH1A1GAAKMT2A | |
| SCHEMBL5428460 | 0.75 | SIGMAR1 (0.46) | TSHRPPARGKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5441821 | 0.74 | MAPT (0.52) | PPARAPPARGKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005049589-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2005-06-02 | — | — | WO | claimed |
| US-20070275956-A1 | Novel Heterocyclic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2007-11-29 | — | — | US | disclosed |
| WO-2005049589-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275956-A1 | Novel Heterocyclic Compounds | CYP46A1, DHCR7, NPC1L1 | TSHR 2961/4885PPARA 990/4885PPARG 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.